- Protalix BioTherapeutics (PLX, Financial) joins the Russell 3000® and 2000® Indexes effective June 27, 2025.
- The inclusion enhances visibility and exposure to approximately $10.6 trillion in benchmarked assets.
- The Russell indexes rank the 4,000 largest US stocks based on market capitalization.
Protalix BioTherapeutics, Inc. (PLX), a leader in plant cell-based protein expression systems, has been added to the Russell 3000® and Russell 2000® Indexes. This significant inclusion took effect on June 27, 2025, as part of the annual reconstitution of the Russell indexes. This membership is a crucial development for Protalix, as it heightens the company's visibility among institutional investors and aligns with $10.6 trillion in indexed assets.
The Russell 3000® Index is designed to encapsulate the 4,000 largest US stocks by market capitalization, with membership lasting for one year. This automatically includes them in either the large-cap Russell 1000® Index or the small-cap Russell 2000® Index along with corresponding growth and value style indexes. The indexes are widely utilized by investment managers and institutional investors for structuring index funds and benchmarking active investment strategies.
Dror Bashan, President and CEO of Protalix, expressed satisfaction with the inclusion, citing the strategic advantage of enhanced market visibility as the company continues its trajectory in the biopharmaceutical sector. Protalix specializes in the development of recombinant therapeutic proteins through its proprietary ProCellEx® system, holding a noteworthy position as the first company to receive FDA approval for a protein produced using a plant cell-based suspension system.
This development follows Protalix's strategic agreements with major pharmaceutical entities such as Pfizer Inc. and Chiesi Farmaceutici S.p.A., pointing towards a promising future leveraging its innovative biotechnological advancements.
